India Globalization Capital (NYSE MKT: IGC), a first mover in the cannabis-based combination therapy space, recently announced that it is readying a line of cannabis-based medical dispensary products that target Alzheimer’s disease (http://nnw.fm/l2NJw). IGC is engineering genetic cell lines which demonstrate that, at various concentrations of tetrahydrocannabinol (THC), the protein Aβ decreases as much as 40 percent without neuron damage. An article discussing this reads: “This compelling in vitro data, and the promise it shows as a preventative and powerful treatment against Alzheimer’s, makes IGC a company with valuation growth potential for investors. The commercial potential for an Alzheimer’s treatment or prevention drug is in the billions of dollars. Investors have made Alzheimer’s drugs a high biotechnology priority.”
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Read More